The search for peripheral disease markers in psychiatry by genomic and proteomic approaches
- PMID: 23489310
- DOI: 10.1517/17530059.1.2.235
The search for peripheral disease markers in psychiatry by genomic and proteomic approaches
Abstract
Clinical practice in psychiatry suffers from a lack of objective measures that could complement the clinical evaluation of the patient. The search for peripheral markers reflecting psychiatric disease state and trait has been under constant scrutiny for a few decades and numerous candidates have been tested based on several disease pathogenesis hypotheses. However, the results have often been of poor outcome or not replicable. Recent developments in proteomic and genomic approaches are expanding the number of testable hypotheses by some orders of magnitude and are allowing for the identification of patterns or signatures, rather than single markers, thus creating the premises for a paradigm shift in the search for biomarkers in psychiatry. A series of studies documenting the potential offered by large-scale transcription analyses and proteomic profiling in a number of psychiatric disorders are reported in this review. Specific applications of microarrays to CNS disorders to generate blood-derived disease signatures are discussed. Future progresses in genome- and proteome-wide investigations of peripheral samples and their integration with genetic and imaging studies will increase the chance of identifying non-invasive diagnostic tests providing clinicians with an integrated biological view of the psychiatric patients.
Similar articles
-
Perfusion magnetic resonance imaging in psychiatry.Top Magn Reson Imaging. 2008 Apr;19(2):111-30. doi: 10.1097/RMR.0b013e3181808140. Top Magn Reson Imaging. 2008. PMID: 19363433 Review.
-
Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges.Expert Rev Proteomics. 2012 Jun;9(3):249-65. doi: 10.1586/epr.12.25. Expert Rev Proteomics. 2012. PMID: 22809205 Review.
-
Urological malignancies and the proteomic-genomic interface.Electrophoresis. 1999 Dec;20(18):3629-37. doi: 10.1002/(SICI)1522-2683(19991201)20:18<3629::AID-ELPS3629>3.0.CO;2-S. Electrophoresis. 1999. PMID: 10612290 Review.
-
Predictive and diagnostic genetic testing in psychiatry.Psychiatr Clin North Am. 2010 Mar;33(1):225-43. doi: 10.1016/j.psc.2009.10.001. Psychiatr Clin North Am. 2010. PMID: 20159347 Review.
-
Prostate cancer biomarkers: a current perspective.Expert Rev Mol Diagn. 2003 Jul;3(4):459-70. doi: 10.1586/14737159.3.4.459. Expert Rev Mol Diagn. 2003. PMID: 12877385 Review.
Cited by
-
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.Transl Psychiatry. 2019 Aug 2;9(1):182. doi: 10.1038/s41398-019-0521-7. Transl Psychiatry. 2019. PMID: 31375659 Free PMC article. Clinical Trial.
-
Comparison of serum protein profiles between major depressive disorder and bipolar disorder.BMC Psychiatry. 2020 Apr 3;20(1):145. doi: 10.1186/s12888-020-02540-0. BMC Psychiatry. 2020. PMID: 32245436 Free PMC article.
-
Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis.Biomark Res. 2015 Feb 6;3:3. doi: 10.1186/s40364-015-0028-1. eCollection 2015. Biomark Res. 2015. PMID: 25729574 Free PMC article.
-
Identification and Characterization of Elevated Expression of Transferrin and Its Receptor TfR1 in Mouse Models of Depression.Brain Sci. 2022 Sep 20;12(10):1267. doi: 10.3390/brainsci12101267. Brain Sci. 2022. PMID: 36291201 Free PMC article.
-
Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidity.PLoS One. 2015 Mar 3;10(3):e0118610. doi: 10.1371/journal.pone.0118610. eCollection 2015. PLoS One. 2015. PMID: 25734326 Free PMC article.
LinkOut - more resources
Full Text Sources